Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Collegium Pharmaceutical (COLL) Accumulated Depreciation & Amortization (2016 - 2025)

Collegium Pharmaceutical (COLL) has 9 years of Accumulated Depreciation & Amortization data on record, last reported at $13.5 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 39.84% year-over-year to $13.5 million; the TTM value through Dec 2024 reached $13.5 million, up 39.84%, while the annual FY2024 figure was $13.5 million, 39.84% up from the prior year.
  • Accumulated Depreciation & Amortization reached $13.5 million in Q4 2024 per COLL's latest filing, up from $9.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $13.5 million in Q4 2024 and bottomed at $3.1 million in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $7.5 million, with a median of $6.3 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 33.57% in 2020, then soared 53.66% in 2021.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.1 million in 2020, then surged by 53.66% to $4.7 million in 2021, then soared by 34.65% to $6.3 million in 2022, then soared by 53.06% to $9.7 million in 2023, then surged by 39.84% to $13.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $13.5 million in Q4 2024, $9.7 million in Q4 2023, and $6.3 million in Q4 2022.